Profile image
Story Views

Last Hour:
Last 24 Hours:

Chong Kun Dang Pharmaceutical Corp – Product Pipeline Review – 2016

Wednesday, March 8, 2017 19:38
% of readers think this story is Fact. Add your two cents.

(Before It's News)

MarketResearchReportStore adds “Chong Kun Dang Pharmaceutical Corp – Product Pipeline Review – 2016″ latest studies, published in March 2017. It is a professional and in-depth study on the current state.


For a sample of this report, please email at: 




‘Chong Kun Dang Pharmaceutical Corp – Product Pipeline Review – 2016’, provides an overview of the Chong Kun Dang Pharmaceutical Corp’s pharmaceutical research and development focus.


The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.


The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.




- The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp

- The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report assesses Chong Kun Dang Pharmaceutical Corp’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report features Chong Kun Dang Pharmaceutical Corp’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects


Request Sample Copy, please email at: 


Table Of Contents

Chong Kun Dang Pharmaceutical Corp Snapshot 6

Chong Kun Dang Pharmaceutical Corp Overview 6

Key Facts 6

Chong Kun Dang Pharmaceutical Corp – Research and Development Overview 7

Key Therapeutic Areas 7

Chong Kun Dang Pharmaceutical Corp – Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products – Monotherapy 11

Pipeline Products – Combination Treatment Modalities 12

Chong Kun Dang Pharmaceutical Corp – Pipeline Products Glance 13

Chong Kun Dang Pharmaceutical Corp – Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Chong Kun Dang Pharmaceutical Corp – Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Chong Kun Dang Pharmaceutical Corp – Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Chong Kun Dang Pharmaceutical Corp – Drug Profiles 17

(amlodipine besylate + candesartan cilexetil) – Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

(atorvastatin calcium + choline fenofibrate) – Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

(atorvastatin calcium + ezetimibe) – Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

(lobeglitazone + metformin hydrochloride XR) – Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

(tadalafil + tamsulosin hydrochloride) – Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

CKD-390 – Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23


Browse Complete Report with TOC @


For report sample or more information, please feel free to contact us:

Shirley | Sales Director

Call: +00-1-626-3463946 - U.S   




About Us

Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.

Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.